Alkem MedTech, the medical devices arm of Alkem Laboratories, has moved to acquire a controlling stake in Swiss cardiac device maker Occlutech Holding AG by signing a binding agreement to purchase up to 55 % of the company for €99.4 million (approximately ₹1,074 crore).
The transaction remains subject to customary regulatory and statutory approvals and is expected to close by June 2026.
The acquisition marks Alkem MedTech’s entry into the global structural heart devices market and significantly expands its footprint beyond its existing product portfolio. Occlutech specialises in minimally invasive cardiac implants used in the treatment of congenital heart disease, stroke prevention and heart failure, and is ranked among the top companies in its segment in Europe and globally.
Occlutech’s operations include manufacturing and research facilities in Germany and Turkey, a global distribution hub in Sweden and clinical activities in the United States, with most revenue derived from Europe and the U.S. in the last financial year.
The deal positions Alkem MedTech to leverage Occlutech’s established capabilities as it expands into high-value international markets and advances its global medical device strategy.
Also Read